1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Marinus Considers Its Options After Mixed Phase III Data

 
• By Joseph Haas

Ganaxolone met one of two endpoints in its Phase III refractory status epilepticus trial, but next steps are uncertain. Analysts say the firm should focus on a more promising trial, but Marinus thinks conditional approval is possible.

Seizures
Marinus is looking to add more seizure indications to ganaxolone's label • Source: Shutterstock

Marinus Pharmaceuticals, Inc. got mixed results on 17 June from a Phase III trial of the intravenous formulation of neuroactive steroid ganaxolone in the rare severe seizure condition refractory status epilepticus (RSE), but it is unclear what its next steps will be. Multiple analysts recommended the company focus primarily on an expected Phase III readout of oral ganaxolone in tuberous sclerosis complex (TSC), which may offer Marinus the best near-term market potential.

Key Takeaways

  • Marinus hits one of two co-primary endpoints with I.V. ganaxolone in refractory status epilepticus, and is pondering another study or seeking conditional approval.

Formed in 2003, Marinus has been focused solely on development of ganaxolone, a positive allosteric modulator of GABA alpha, enduring...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

BioMarin’s Roctavian Continues to Shine In Hemophilia A Despite Commercial Woes

 
• By Sushmita Panda

Roctavian shows durable bleed control and safety over five years, but high costs and access hurdles limit its commercial outlook.

Dizal’s Zegfrovy Wins US NSCLC Approval, At Lower Dose Than In China

 
• By Dexter Jie Yan

Dizal's EGFR inhibitor Zegfrovy approved in US as new once-daily oral option for second-line NSCLC with EGFR exon 20 insertion mutations, at lower dose than in China.

Novartis’s Cosentyx Suffers Rare Phase III Fail

 
• By Kevin Grogan

Multi-blockbuster falls short in a giant cell arteritis study.

In Brief: Organon To Pull Plug On OG-6219 Program After Phase II Endometriosis Trial Failure

 
• By Sushmita Panda

Once hailed as a potential game changer, OG-6219 gets the axe after failing in a Phase II endometriosis-related pain trial.

More from R&D

In Brief: 4DMT Fast-Tracks Long-Acting Wet AMD Therapy Trials, Cuts 25% Of Workforce

 
• By Sushmita Panda

4D Molecular Therapeutics has fast-tracked its Phase III trials for 4D-150 in wet AMD, with top-line data from one now expected in H1 2027 and another underway ahead of schedule. The company is also cutting a quarter of its staff as it focuses on its late-stage pipeline and to help fund the trials.

Beyond AI Hype: Tokyo-1’s Real Answer On How To Innovate Pharma R&D

 
• By Lisa Takagi

Bringing supercomputing power to bear on large-scale calculations for pharma R&D, Tokyo-based Xeureka explains the practical use of AI to empower innovation beyond the hype.

In Brief: Atai-Beckley Deal Marches On After Phase II Psychedelic Win

 
• By Manas Mishra

The psychedelic therapy firms pass a key condition for their planned merger after the antidepressant BPL-003 meets the main endpoints of a Phase IIb trial.